EL7.AI
Stocks•4 June 2026•
1 min read

Mirum Pharmaceuticals to Present Zilurgisertib Data Ahead of FDA Decision

Key Facts

1Pivotal Phase 2 results for zilurgisertib in treating rare disease FOP will be presented at ENDO 2026.
2The FDA has set a PDUFA action date of September 26, 2026, for the zilurgisertib New Drug Application.

In a move reflecting the high stakes of rare disease drug development, Mirum Pharmaceuticals has announced the upcoming presentation of pivotal Phase 2 data for zilurgisertib. According to reports, the clinical results for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) will be showcased at the ENDO 2026 conference. Furthermore, the U.S. Food and Drug Administration (FDA) has established September 26, 2026, as the PDUFA action date for the drug's New Drug Application.

This announcement comes as sector peers like Incyte, a partner in the drug's development, continue to strengthen their specialized treatment portfolios. Compared to broader biotech trends, Mirum is positioning itself within the lucrative orphan drug market. Per market data, successful Phase 2 outcomes are often viewed by investors as a de-risking milestone ahead of major regulatory deadlines, particularly given the drug's Priority Review status granted by the FDA.

Traders should closely monitor market reactions to the detailed clinical data released during the conference as a near-term catalyst. Looking ahead, the FDA decision on September 26, 2026, remains the primary fundamental driver for the stock.